Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application

Description

List of Tables

[190 Pages Report] The Neoantigen Cancer Vaccine Market size was estimated at USD 57.14 million in 2023 and expected to reach USD 60.44 million in 2024, at a CAGR 5.17% to reach USD 81.35 million by 2030.

Global Neoantigen Cancer Vaccine Market

KEY MARKET STATISTICS
Base Year [2023]	USD 57.14 million
Estimated Year [2024]	USD 60.44 million
Forecast Year [2030]	USD 81.35 million
CAGR (%)	5.17%

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neoantigen Cancer Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neoantigen Cancer Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neoantigen Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include ", "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc., Advaxis Inc., Agenus Inc., AstraZeneca plc, Avidea Technologies, BioLineRx, BioNTech SE, Brightpath Biotherapeutics Co., Ltd., CureVac N.V., Elicio Therapeutics Inc, F. Hoffmann-La Roche Ltd., Genocea Biosciences Inc, Gilead Sciences, Inc., Gritstone bio, Inc., Immunomic Therapeutics, Inc., IMV Inc, ISA Pharmaceuticals BV, Medigene AG, Merck & Co., Inc., Neophore Limited, Nouscom, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis srl.

Market Segmentation & Coverage

This research report categorizes the Neoantigen Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Off-The Shell Neoantigen Vaccine
- Personalized Neo-Antigen Vaccine
Technology
- HLA Typing
- RNA Sequencing
- Whole Genome Sequencing
Delivery Mechanism
- Electroporation
- Gene Gun
- Liposomes
- Virosomes
Neoantigen Type
- Dendritic Cell
- Nucleic Acid
- Synthetic Long Peptide
- Tumor Cell
Route of Administration
- Intramuscular
- Intravenous
- Transdermal
Application
- Brain Cancer
- Gastrointestinal Cancer
- Lung Cancer
- Melanoma
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Neoantigen Cancer Vaccine Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neoantigen Cancer Vaccine Market?

3. What are the technology trends and regulatory frameworks in the Neoantigen Cancer Vaccine Market?

4. What is the market share of the leading vendors in the Neoantigen Cancer Vaccine Market?

5. Which modes and strategic moves are suitable for entering the Neoantigen Cancer Vaccine Market?

Product Code: MRR-5C6F41F5B004

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Neoantigen Cancer Vaccine Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of cancer globally
  - 5.1.1.2. Improvements in genomic sequencing and immunotherapy
  - 5.1.1.3. Inclination towards early diagnosis and treatment of cancer
- 5.1.2. Restraints
  - 5.1.2.1. High cost and complexity in manufacturing
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing R&D to improve efficacy of neoantigen cancer vaccine
  - 5.1.3.2. Emerging development of combination therapies
- 5.1.4. Challenges
  - 5.1.4.1. Adverse effects and ethical issues
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Neoantigen Cancer Vaccine Market, by Product

6.1. Introduction
6.2. Off-The Shell Neoantigen Vaccine
6.3. Personalized Neo-Antigen Vaccine

7. Neoantigen Cancer Vaccine Market, by Technology

7.1. Introduction
7.2. HLA Typing
7.3. RNA Sequencing
7.4. Whole Genome Sequencing

8. Neoantigen Cancer Vaccine Market, by Delivery Mechanism

8.1. Introduction
8.2. Electroporation
8.3. Gene Gun
8.4. Liposomes
8.5. Virosomes

9. Neoantigen Cancer Vaccine Market, by Neoantigen Type

9.1. Introduction
9.2. Dendritic Cell
9.3. Nucleic Acid
9.4. Synthetic Long Peptide
9.5. Tumor Cell

10. Neoantigen Cancer Vaccine Market, by Route of Administration

10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Transdermal

11. Neoantigen Cancer Vaccine Market, by Application

11.1. Introduction
11.2. Brain Cancer
11.3. Gastrointestinal Cancer
11.4. Lung Cancer
11.5. Melanoma

12. Americas Neoantigen Cancer Vaccine Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Neoantigen Cancer Vaccine Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player

16. Competitive Portfolio

16.1. Key Company Profiles
- 16.1.1. "
- 16.1.2. "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
- 16.1.3. Advaxis Inc.
- 16.1.4. Agenus Inc.
- 16.1.5. AstraZeneca plc
- 16.1.6. Avidea Technologies
- 16.1.7. BioLineRx
- 16.1.8. BioNTech SE
- 16.1.9. Brightpath Biotherapeutics Co., Ltd.
- 16.1.10. CureVac N.V.
- 16.1.11. Elicio Therapeutics Inc
- 16.1.12. F. Hoffmann-La Roche Ltd.
- 16.1.13. Genocea Biosciences Inc
- 16.1.14. Gilead Sciences, Inc.
- 16.1.15. Gritstone bio, Inc.
- 16.1.16. Immunomic Therapeutics, Inc.
- 16.1.17. IMV Inc
- 16.1.18. ISA Pharmaceuticals BV
- 16.1.19. Medigene AG
- 16.1.20. Merck & Co., Inc.
- 16.1.21. Neophore Limited
- 16.1.22. Nouscom
- 16.1.23. Nykode Therapeutics ASA
- 16.1.24. OSE Immunotherapeutics
- 16.1.25. Takis srl
16.2. Key Product Portfolio

17. Appendix

17.1. Discussion Guide
17.2. License & Pricing